Documentation of Safety and Efficacy of Synagis in Preterm Infants.

Trial Profile

Documentation of Safety and Efficacy of Synagis in Preterm Infants.

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Aug 2016

At a glance

  • Drugs Palivizumab (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Therapeutic Use
  • Sponsors Abbott Laboratories; AbbVie
  • Most Recent Events

    • 15 Aug 2016 Status changed from recruiting to completed.
    • 19 May 2014 Planned end date changed from 1 May 2015 to 1 May 2017 as reported by ClinicalTrials.gov.
    • 03 Jun 2013 Planned End Date changed from 1 Jun 2015 to 1 May 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top